About: Seladelpar

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Seladelpar (INN, USAN; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV.

Property	Value
dbo:abstract	Seladelpar (INN, USAN; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV. (en)
dbo:casNumber	851528-79-5
dbo:chEMBL	230158
dbo:drugbank	DB12390
dbo:fdaUniiCode	7C00L34NB9
dbo:kegg	D11256
dbo:pubchem	11236126
dbo:thumbnail	wiki-commons:Special:FilePath/Seladelpar.svg?width=300
dbo:wikiPageExternalLink	http://adisinsight.springer.com/drugs/800024671
dbo:wikiPageID	38991375 (xsd:integer)
dbo:wikiPageLength	3428 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1033003025 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Metabolic_syndrome dbr:Dyslipidemia dbc:Carboxylic_acids dbc:Experimental_drugs dbc:Trifluoromethyl_compounds dbr:Elafibranor dbr:GW501516 dbr:Diabetes_mellitus_type_2 dbr:Press_release dbr:Non-alcoholic_fatty_liver_disease dbr:Janssen_Pharmaceutica dbc:PPAR_agonists dbr:Peroxisome_proliferator-activated_receptor dbr:Peroxisome_proliferator-activated_receptor_delta dbr:Receptor_agonist
dbp:atcPrefix	None (en)
dbp:c	21 (xsd:integer)
dbp:casNumber	851528 (xsd:integer)
dbp:chembl	230158 (xsd:integer)
dbp:chemspiderid	9411171 (xsd:integer)
dbp:drugbank	DB12390 (en)
dbp:f	3 (xsd:integer)
dbp:h	23 (xsd:integer)
dbp:iupacName	2 (xsd:integer)
dbp:kegg	D11256 (en)
dbp:legalStatus	Investigational (en)
dbp:o	5 (xsd:integer)
dbp:pubchem	11236126 (xsd:integer)
dbp:s	1 (xsd:integer)
dbp:smiles	CCO[C@H]CSC2=CCC (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	JWHYSEDOYMYMNM-QGZVFWFLSA-N (en)
dbp:synonyms	MBX-8025; RWJ-800025 (en)
dbp:unii	7 (xsd:integer)
dbp:width	250 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Gastrointestinal-drug-stub dbt:Drugbox dbt:PPAR_modulators dbt:Reflist dbt:Abbrlink
dcterms:subject	dbc:Carboxylic_acids dbc:Experimental_drugs dbc:Trifluoromethyl_compounds dbc:PPAR_agonists
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Seladelpar (INN, USAN; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV. (en)
rdfs:label	Seladelpar (en)
owl:sameAs	wikidata:Seladelpar https://global.dbpedia.org/id/2Ydhn
prov:wasDerivedFrom	wikipedia-en:Seladelpar?oldid=1033003025&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Seladelpar.svg
foaf:isPrimaryTopicOf	wikipedia-en:Seladelpar
is dbo:wikiPageRedirects of	dbr:MBX-8025 dbr:MBX8025 dbr:MBX_8025 dbr:RWJ-800,025 dbr:RWJ-800025 dbr:RWJ800025 dbr:RWJ_800,025 dbr:RWJ_800025
is dbo:wikiPageWikiLink of	dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:MBX-8025 dbr:MBX8025 dbr:MBX_8025 dbr:RWJ-800,025 dbr:RWJ-800025 dbr:RWJ800025 dbr:RWJ_800,025 dbr:RWJ_800025
is foaf:primaryTopic of	wikipedia-en:Seladelpar